Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/112554
Título: Should methyldibromo glutaronitrile continue to be used in the European baseline Series? A REIDAC national cross-sectional study
Autores/as: Mercader-García, Pedro
Pastor-Nieto, María Antonia
Gonzalez-Perez, Ricardo
Cordoba-Guijarro, Susana
Gimenez-Arnau, Ana María
Ruiz-Gonzalez, Inmaculada
Mora-Fernandez, Verónica
Miquel, Javier
Silvestre-Salvador, Juan Francisco
Ortiz-Frutos, Francisco Javier
Sanz-Sánchez, Tatiana
Rodríguez-Serna, Mercedes
Pérez-Feal, Patricia
Sánchez Pérez, Javier
Heras-Mendaza, Felipe
Serra-Baldrich, Ester
Zaragoza-Ninet, Violeta
Hervella-Garces, Marcos
Gatica-Ortega, María Elena
García-Doval, Ignacio
Descalzo, Miguel Ángel
Borrego Hernando, Leopoldo 
Clasificación UNESCO: 32 Ciencias médicas
320106 Dermatología
Palabras clave: Allergic contact dermatitis
Clinical relevance
Cross-sectional study
Methyldibromo glutaronitrile
Patch tests
Fecha de publicación: 2021
Publicación seriada: Contact Dermatitis 
Resumen: Background Methyldibromo glutaronitrile (MDBGN) was one of the most frequent and relevant allergens found in patch testing at the beginning of this century. In 2008, this preservative was banned from cosmetics in Europe and ever since the prevalence of contact allergy to MDBGN has progressively decreased. Despite that gradual decline, MDBGN is still patch-tested in most baseline series. This study assessed the frequency of MDBGN sensitization, epidemiological characteristics of allergic patients, and the relevance of positive patch tests in a nationwide Spanish registry (REIDAC). Patients and methods We evaluated consecutively patch-tested patients in all participating centres. Using these data, we calculated the proportion of patients with positive patch tests to MDBGN from June 2018 to June 2020 and evaluated the relevance of the positive patch tests. Results One hundred and fourteen out of 5072 (2.24 %) tested patients were sensitized to MDBGN. Clinical current relevance was confirmed in only one case. Conclusion Although the frequency of contact allergy to MDBGN remains high, no clinical significance was found in most of these patients (5072 tests needed to obtain one relevant positive result). The clinical usefulness of this allergen seems weak and its continued inclusion in the European baseline series is questionable.
URI: http://hdl.handle.net/10553/112554
ISSN: 0105-1873
DOI: 10.1111/cod.13837
Fuente: Contact Dermatitis [ISSN 0105-1873], v. 85 (5), p. 572-577 (Noviembre 2021)
Colección:Artículos
Adobe PDF (1,61 MB)
Vista completa

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.